Welcome to our dedicated page for eToro Group Ltd. SEC filings (Ticker: ETOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on eToro Group Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into eToro Group Ltd.'s regulatory disclosures and financial reporting.
eToro Group Ltd. filed a Form 6-K to announce the appointment of two new directors. The press release (Exhibit 99.1) states that former U.S. SEC Commissioner Laura Unger and Wix.com Chief Financial Officer Lior Shemesh have joined the Company鈥檚 board. The filing clarifies that the press release is furnished, not filed, and will be incorporated by reference into the Company鈥檚 Form S-8 registration statement. No financial data, guidance, or strategic commentary accompanies the governance update.
The document is purely a corporate governance disclosure; it contains no earnings information, no transactions, and no further detail beyond the identities and titles of the new board members. Management executed the filing on 3 July 2025, with CEO Jonathan Alexander Assia signing on behalf of the registrant.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) has completed the second and final closing of its previously announced private placement, bringing aggregate gross proceeds to approximately $5.7 million. The financing consists of 6% convertible promissory notes maturing on July 28, 2026 and common stock warrants. The June 30 closing added roughly $3.4 million to the $2.3 million first tranche that closed on June 12, 2025.
Key terms
- Conversion mechanics: Notes (plus accrued interest) convert at 80% of the 5-day average Nasdaq closing price on the earlier of (i) 30 days after a planned reverse split (expected July 27, 2025) or (ii) the one-year note anniversary, capped at $11.20 per share.
- Investor protection: Holders that would exceed 4.99% or 9.99% ownership limits will receive $0.01 pre-funded warrants instead of shares.
- Warrant coverage: Investors receive five-year warrants equal to 200% of the conversion shares, exercisable at the same conversion price. Placement agent Paulson Investment Company earns cash fees of 12% plus warrants for 12% of the conversion shares.
- Use of proceeds: Fund Phase 1b/2 clinical trial, working capital and general corporate purposes.
- Shareholder approval: To comply with Nasdaq Rule 5635(d), a special meeting is set for July 25, 2025 to authorize share issuance above the 19.99% cap.
The company must file a resale registration statement within 30 days of conversion and keep it effective for up to two years. The structure raises near-term capital but embeds significant potential dilution and a 20% conversion discount that favors investors.
FAQ
What is the current stock price of eToro Group Ltd. (ETOR)?
What is the market cap of eToro Group Ltd. (ETOR)?
